Richard B Pearson Selected Research

RNA Polymerase I (Polymerase I, RNA)

11/2021	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition.
1/2021	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
11/2020	Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis.
1/2020	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461.
1/2019	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.
1/2017	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
11/2016	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
8/2016	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription.
2/2015	Regulation of rDNA transcription in response to growth factors, nutrients and energy.
6/2014	Targeting the nucleolus for cancer intervention.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard B Pearson Research Topics

Disease

48	Neoplasms (Cancer) 01/2022 - 11/2004
9	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 12/2006
7	Lymphoma (Lymphomas) 01/2021 - 07/2012
6	Melanoma (Melanoma, Malignant) 01/2022 - 04/2014
5	Hematologic Neoplasms (Hematological Malignancy) 11/2020 - 07/2012
4	Prostatic Neoplasms (Prostate Cancer) 11/2021 - 11/2016
4	Leukemia 01/2019 - 07/2012
4	Carcinogenesis 01/2018 - 01/2013
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 04/2013
3	Carcinoma (Carcinomatosis) 01/2018 - 10/2002
2	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2017
1	Stomach Neoplasms (Stomach Cancer) 01/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 01/2020
1	Neuroblastoma 01/2020
1	Vomiting 01/2019
1	Nausea 01/2019
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2019
1	ATR-X syndrome 01/2018
1	Papilloma (Papillomatosis) 01/2018
1	Starvation 05/2017
1	Genomic Instability 02/2015
1	Hypoxia (Hypoxemia) 04/2014
1	Colorectal Neoplasms (Colorectal Cancer) 01/2014
1	Disease Progression 11/2013
1	Thymoma (Thymic Carcinoma) 01/2013

Drug/Important Bio-Agent (IBA)

13	CX 5461IBA 11/2021 - 07/2012
12	RNA Polymerase I (Polymerase I, RNA)IBA 11/2021 - 07/2012
10	Ribosomal DNA (rDNA)IBA 01/2020 - 07/2012
8	Mechanistic Target of Rapamycin Complex 1IBA 01/2020 - 09/2008
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2013
5	Transcription Factors (Transcription Factor)IBA 01/2020 - 11/2011
5	Phosphotransferases (Kinase)IBA 11/2016 - 11/2004
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2021 - 01/2018
4	Ribosomal RNAIBA 01/2020 - 11/2013
4	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2013 - 11/2004
3	palbociclibIBA 01/2019 - 07/2014
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 12/2013
2	CystathionineIBA 01/2022 - 01/2018
2	Androgen Receptors (Androgen Receptor)IBA 11/2021 - 11/2018
2	DNA-Directed RNA Polymerases (RNA Polymerase)IBA 01/2021 - 05/2013
2	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 08/2012
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	ChromatinIBA 01/2020 - 01/2019
2	Estrogen ReceptorsIBA 01/2019 - 11/2004
2	Histones (Histone)IBA 01/2018 - 02/2015
2	Pharmaceutical PreparationsIBA 01/2018 - 08/2015
2	RNA (Ribonucleic Acid)IBA 01/2017 - 11/2016
2	Everolimus FDA Link 01/2016 - 01/2013
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2013 - 12/2006
2	Small Interfering RNA (siRNA)IBA 03/2013 - 04/2011
2	LipidsIBA 12/2012 - 11/2004
2	Tyrosine (L-Tyrosine)FDA Link 05/2011 - 10/2002
1	Messenger RNA (mRNA)IBA 01/2022
1	talazoparibIBA 11/2021
1	Dactinomycin (Actinomycin)FDA LinkGeneric 01/2021
1	Ribosomal Proteins (Ribosomal Protein)IBA 01/2021
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 01/2019
1	Cyclin-Dependent Kinase 4IBA 01/2019
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 01/2019
1	CalciumIBA 01/2019
1	Antineoplastic Agents (Antineoplastics)IBA 01/2019
1	abirateroneIBA 11/2018
1	enzalutamideIBA 11/2018
1	rucaparibIBA 01/2018
1	HeterochromatinIBA 01/2018
1	MTOR InhibitorsIBA 01/2018
1	HomocysteineIBA 01/2018
1	dinaciclibIBA 04/2017
1	CyclinsIBA 04/2017
1	Cyclin-Dependent Kinase 2IBA 04/2017
1	CX-6258IBA 11/2016
1	proto-oncogene proteins pimIBA 11/2016
1	Amino Acids FDA Link 08/2016
1	Eukaryotic Initiation Factor-4EIBA 01/2016
1	JNK Mitogen-Activated Protein KinasesIBA 08/2015
1	tubulin-specific chaperone CIBA 08/2015
1	Proto-Oncogene Proteins B-rafIBA 08/2015
1	Retinoblastoma ProteinIBA 07/2014
1	Glucose (Dextrose)FDA LinkGeneric 04/2014
1	Calcibiotic Root Canal SealerIBA 01/2014
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 01/2014
1	PlatinumIBA 12/2013
1	mirdametinibIBA 12/2013
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2013
1	TOR Serine-Threonine KinasesIBA 12/2013
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2013
1	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 12/2013
1	MK 2206IBA 11/2013
1	Indicators and Reagents (Reagents)IBA 08/2013
1	dactolisibIBA 04/2013
1	Therapeutic UsesIBA 03/2013
1	Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA 01/2013
1	Sirolimus (Rapamycin)FDA Link 01/2013
1	Serine (L-Serine)FDA Link 12/2012
1	liposomal doxorubicin (Doxil)FDA Link 08/2012

Therapy/Procedure

20	Therapeutics 01/2022 - 01/2012
3	Drug Therapy (Chemotherapy) 01/2019 - 08/2012
2	Castration 11/2018 - 11/2016
1	Oral Administration 11/2016